Volume Alert - ACHN 12.85 Achillion Pharmaceutical
Post# of 94
Posted On: 11/11/2014 12:09:46 AM
Volume Alert - ACHN 12.85 Achillion Pharmaceuticals $ACHN Hit a high today of 12.95 Closing the day 11/10/14 at 12.85 +2.74 +27.10% With a day low of 10.67 and a total volume of 28,839,303.
ACHN Recent Posts: http://investorshangout.com/Achillion-Pharmac...CHN-53213/
ACHN Achillion Pharmaceuticals Recent Headline News
Most active Nasdaq-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
ACHN: 12.85 (+2.74), DNDN: 0.18 (-0.76), CMCSK: 52.83 (-2.16), ARCP: 8.50 (-0.29), MSFT: 48.89 (+0.21), INTC: 33.26 (-0.32), CMCSA: 52.95 (-2.20), AAPL: 108.83 (-0.18), CSCO: 25.15 (-0.18)
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.13 (+1.28), PCMI: 8.80 (+1.35), ACHN: 12.85 (+2.74), TGTX: 12.55 (+1.28), AGIO: 81.78 (+9.72), LIOX: 5.54 (+0.80), PLNR: 7.68 (+1.28)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.89 (-1.90), JRJC: 6.44 (+0.93), NAVB: 1.03 (-0.19), SANW: 3.64 (+0.56), PLPM: 1.67 (+0.30), RYN: 28.82 (-5.08), INFU: 2.97 (-0.52), LIOX: 5.54 (+0.80), DY: 27.97 (-2.90), MTZ: 24.93 (-3.70), CGIX: 6.68 (+0.68), MUX: 1.23 (-0.18), OREX: 5.13 (+1.28), URRE: 2.56 (+0.62), ACHN: 12.85 (+2.74), REN: 2.90 (-0.71), MPO: 3.21 (+0.10), AKBA: 8.99 (-1.71), TRX: 1.04 (-0.18), PLNR: 7.68 (+1.28)
Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST
ACHN: 12.85 (+2.74)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST
PT: 1.64 (+0.12), GPRO: 75.75 (-3.31), OREX: 5.13 (+1.28), GOGO: 18.40 (+1.76), JRJC: 6.44 (+0.93), UEC: 1.90 (+0.18), ACHN: 12.85 (+2.74), ARQL: 1.17 (+0.11), CMCM: 20.56 (+0.36), IBIO: 1.23 (+0.07), DF: 16.40 (+1.98)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.85 (+2.74)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.85 (+2.74)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.04 (+0.02), HSKA: 16.40 (+0.50), ACHN: 12.85 (+2.74), AMAG: 34.91 (-0.04)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.85 (+2.74)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.18 (+3.34), CYTX: 0.40 (-0.03), ACHN: 12.85 (+2.74), INCY: 70.96 (+1.64), SRPT: 16.04 (-0.08)
ACHN Recent Posts: http://investorshangout.com/Achillion-Pharmac...CHN-53213/
ACHN Achillion Pharmaceuticals Recent Headline News
Most active Nasdaq-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
ACHN: 12.85 (+2.74), DNDN: 0.18 (-0.76), CMCSK: 52.83 (-2.16), ARCP: 8.50 (-0.29), MSFT: 48.89 (+0.21), INTC: 33.26 (-0.32), CMCSA: 52.95 (-2.20), AAPL: 108.83 (-0.18), CSCO: 25.15 (-0.18)
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.13 (+1.28), PCMI: 8.80 (+1.35), ACHN: 12.85 (+2.74), TGTX: 12.55 (+1.28), AGIO: 81.78 (+9.72), LIOX: 5.54 (+0.80), PLNR: 7.68 (+1.28)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.89 (-1.90), JRJC: 6.44 (+0.93), NAVB: 1.03 (-0.19), SANW: 3.64 (+0.56), PLPM: 1.67 (+0.30), RYN: 28.82 (-5.08), INFU: 2.97 (-0.52), LIOX: 5.54 (+0.80), DY: 27.97 (-2.90), MTZ: 24.93 (-3.70), CGIX: 6.68 (+0.68), MUX: 1.23 (-0.18), OREX: 5.13 (+1.28), URRE: 2.56 (+0.62), ACHN: 12.85 (+2.74), REN: 2.90 (-0.71), MPO: 3.21 (+0.10), AKBA: 8.99 (-1.71), TRX: 1.04 (-0.18), PLNR: 7.68 (+1.28)
Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST
ACHN: 12.85 (+2.74)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST
PT: 1.64 (+0.12), GPRO: 75.75 (-3.31), OREX: 5.13 (+1.28), GOGO: 18.40 (+1.76), JRJC: 6.44 (+0.93), UEC: 1.90 (+0.18), ACHN: 12.85 (+2.74), ARQL: 1.17 (+0.11), CMCM: 20.56 (+0.36), IBIO: 1.23 (+0.07), DF: 16.40 (+1.98)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline - ACHN: 12.85 (+2.74)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.85 (+2.74)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.04 (+0.02), HSKA: 16.40 (+0.50), ACHN: 12.85 (+2.74), AMAG: 34.91 (-0.04)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.85 (+2.74)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.18 (+3.34), CYTX: 0.40 (-0.03), ACHN: 12.85 (+2.74), INCY: 70.96 (+1.64), SRPT: 16.04 (-0.08)
(0)
(0)